Episode 1874 • • 2:03:34 - 2:06:14
1874: Kennel Index
Eli Lilly, Retatrutide, and Weight Loss Results
Eli Lilly is developing a new obesity medication called Retatrutide, which targets three different hormones (GLP-1, GIP, and glucagon). Clinical trials show patients lost an average of 70 pounds over 80 weeks, significantly outperforming placebos. The hosts discuss whether this is simply a repackaged peptide that is already available through "peptide dealers."